Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 4/20 | 0.42 |
| ▸ | NPY2R | P49146 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.39 |
| ▸ | CCR4 | P51679 | 6/20 | 0.39 |
| ▸ | L3MBTL3 | Q96JM7 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12552673 | 0.88 | RBP4 (0.48) | RBP4TTRKDM4EHPGDHSD17B10 | |
| SCHEMBL5519910 | 0.87 | RBP4 (0.43) | RBP4TTRKDM4EHPGDHSD17B10 | |
| SCHEMBL5524235 | 0.86 | ALDH1A1 (0.45) | RBP4TTRKDM4EHPGDHSD17B10 | |
| SCHEMBL12552663 | 0.84 | MAPK1 (0.43) | KDM4EHPGDHSD17B10MCHR1L3MBTL3 | |
| SCHEMBL5527465 | 0.84 | KDM4E (0.58) | RBP4TTRKDM4EUSP2HPGD | |
| SCHEMBL5525363 | 0.84 | HRH4 (0.46) | RBP4TTRKDM4EUSP2HPGD | |
| SCHEMBL12552670 | 0.84 | RBP4 (0.55) | RBP4TTRKDM4EUSP2HPGD | |
| SCHEMBL12580645 | 0.79 | CCR4 (0.38) | NPY2RKDM4EHPGDCCR4L3MBTL3 | |
| SCHEMBL1420086 | 0.79 | NPY2R (0.47) | NPY2RHPGDNPSR1MCHR1KCNH2 | |
| SCHEMBL5528147 | 0.78 | PIK3CA (0.47) | KDM4ENPSR1HSD17B10L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110144107-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA | IRM LLC (BM) | 2011-06-16 | — | — | US | disclosed |
| US-20110144107-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA | IRM LLC (BM) | 2011-06-16 | — | — | US | disclosed |
| US-20110144107-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA | IRM LLC (BM) | 2011-06-16 | — | — | US | disclosed |
| EP-2297097-A2 | COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA | IRM LLC (BM) | 2011-03-23 | — | — | EP | disclosed |
| WO-2009152356-A2 | COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA | IRM LLC (BM) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144107-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA | G6PD, DHFR, SGMS1 | RBP4 850/4885NPY2R 4064/4885TTR 878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.